Partnership combines ARTBIO's AlphaDirect™
platform for 212Pb-based alpha radioligand therapies
with 3B Pharmaceuticals' expertise in
peptide radioligand therapy discovery and development
ARTBIO gains exclusive global license for
highly novel program close to clinical development addressing first
in class target in solid tumor indications with high unmet
need
CAMBRIDGE, Mass. and BERLIN, Nov. 14,
2024 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a
clinical-stage radiopharmaceutical company developing a new class
of targeted alpha radioligand therapies (ARTs), and 3B Pharmaceuticals GmbH (3BP), a private
biotechnology company developing targeted radiopharmaceutical drugs
and diagnostics for oncology indications, today announced a
worldwide, exclusive license and research agreement to develop an
advanced preclinical stage first-in-class peptide ART for the
treatment of solid tumors.
This partnership extends ARTBIO's pipeline with the addition of
a highly differentiated program focused on a novel, first-in-class
target that is optimal for 212Pb-based alpha radioligand
therapy. 212Pb has an ideal clinical profile well suited
to this program due to a short half-life and single alpha emission
that delivers maximal energy into tumors.
"In-licensing this first-in-class program from 3BP speaks to our
mission to expand beyond prostate cancer and create a whole new
class of therapies that can improve outcomes for patients with many
types of cancer," said Emanuele
Ostuni, Ph.D., CEO of ARTBIO. "We can achieve this goal by
addressing targets novel to radioligand therapies. By partnering
3BP's proven track record in peptide discovery with our leadership
in 212Pb ART development, we believe we can unlock an
important new target and deliver much-needed patient benefit."
The program has promise across a range of solid tumor
indications where patients have a high need for alternatives and
for which radioligand therapies are not currently in clinical use
or advanced development. ARTBIO will advance the licensed program
through clinical development, starting in 2025, with both companies
contributing their respective expertise to optimize the therapy's
profile.
"By combining our unique and innovative discovery platforms,
we're redefining treatment paradigms for solid tumors," said Dr.
Ulrich Reineke, Managing Director of
3BP. "Our shared vision and complementary contributions will
accelerate the development of this potentially transformative
treatment for patients with solid tumors."
About ARTBIO
ARTBIO is a clinical-stage
radiopharmaceutical company redefining cancer care by creating a
new class of alpha radioligand therapies (ARTs). The unique ARTBIO
approach selects the optimal alpha-precursor isotope
(212Pb) and tumor-specific targets to create
therapeutics with the potential for highest efficacy and safety.
The company's AlphaDirect™ technology, a
first-of-its-kind 212Pb isolation method, enables a
distributed manufacturing approach for the reliable production and
delivery of ARTs. ARTBIO is advancing multiple pipeline programs
with lead program AB001 currently in first-in-human trials. ARTBIO
is shaped by a long-standing scientific legacy with nearly a
century of pioneering work in radiation therapy conducted at
the University of Oslo and
Norway's Radium Hospital. For
more information, visit www.artbio.com, and follow us
on LinkedIn and Twitter.
About 3B
Pharmaceuticals
3B
Pharmaceuticals GmbH is a German biotechnology company developing
innovative therapeutic and diagnostic radiopharmaceuticals for
oncology applications. Using its dedicated technology platform
3BP developed a broad pipeline of novel compounds addressing
innovative as well as established drug targets to deliver
diagnostic and therapeutic radioisotopes to tumors. The
company's mission is to advance the standard of care in
precision oncology through innovative nuclear medicine
solutions that address unmet medical needs. For more information on
3B Pharmaceuticals, visit
www.3b-pharma.com.
ARTBIO Media Contact
Marites
Coulter
Tel: +1 415 819 2214
Email: marites.coulter@deerfieldgroup.com
3B Pharmaceuticals Media
Contact
Dr. Jan Michel
Director Finance & Corporate Development
Tel.: +49 (30) 6392-4317
Fax.: +49 (30) 6392-4316
E-mail: jan.michel@3b-pharma.com
Logo -
https://mma.prnewswire.com/media/2106824/ARTBIO_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/artbio-to-enter-into-licensing-and-research-partnership-with-3b-pharmaceuticals-to-advance-a-first-in-class-alpha-radioligand-therapy-for-solid-tumors-302303411.html
